Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

In the analysis, 46% of patients were taking Novo's Ozempic or Wegovy, both injectable versions of semaglutide. Others were ...

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

The prevalence of obesity continues to remain high in the US, making the demand for effective treatments even more urgent.

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of ...

Oral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular ...